WASHINGTON — Medicare can’t seem to figure out how to pay for pricey CAR-T cancer therapies.
The latest glaring example of the struggle? A daylong advisory meeting Wednesday in Baltimore, ostensibly convened to discuss how patient-reported data should fit into the way Medicare pays for the therapies, devolved into a confusing debate about what the meeting was supposed to be about in the first place.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
